biostar8k030810.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date
of report (Date of earliest event reported): March 8, 2010
BIOSTAR
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in Charter)
Maryland
|
|
333-147363
|
|
20-5101287
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Commission
File No.)
|
|
(IRS
Employer Identification No.)
|
No.
588 Shiji Avenue
Xiangyang
City, Shaanxi Province
People’s
Republic of China 712046
(Address
of Principal Executive Offices)
86-029-33686638
(Issuer Telephone
Number)
N/A
(Former name or
former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Forward
Looking Statements
This Form
8-K and other reports filed by Biostar Pharmaceuticals, Inc. (the “Registrant”)
from time to time with the Securities and Exchange Commission (collectively the
“Filings”) contain forward looking statements and information that are based
upon beliefs of, and information currently available to, the Registrant’s
management as well as estimates and assumptions made by the Registrant’s
management. When used in the Filings the words “anticipate”,
“believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of
these terms and similar expressions as they relate to the Registrant or the
Registrant’s management identify forward looking statements. Such
statements reflect the current view of the Registrant with respect to future
events and are subject to risks, uncertainties, assumptions and other factors
relating to the Registrant’s industry, operations and results of operations and
any businesses that may be acquired by the Registrant. Should one or
more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those
anticipated, believed, estimated, expected, intended or planned.
Although
the Registrant believes that the expectations reflected in the forward looking
statements are reasonable, the Registrant cannot guarantee future results,
levels of activity, performance or achievements. Except as required by
applicable law, including the securities laws of the United States, the
Registrant does not intend to update any of the forward-looking statements to
conform these statements to actual results.
Item 7.01
|
Regulation FD
Disclosure |
On March
8, 2010, the Registrant delivered a presentation at the Rodman & Renshaw
Annual China Investment Conference in Beijing, China. A copy of the presentation
materials used in connection with the presentation is attached hereto as
Exhibits 99.1 and 99.2 and incorporated herein by reference.
The
information in this Form 8-K, including the presentation materials attached
hereto as Exhibits 99.1 and 99.2, is being furnished pursuant to Item 7.01 and
shall not be deemed "filed" for the purposes of Section 18 of the Securities and
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that Section. The information in this Form 8-K shall not be incorporated by
reference into any registration statement pursuant to the Securities Act of
1933, as amended.
Item 9.01
|
Financial
Statement and Exhibits
|
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
|
99.2
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: March
9, 2010
|
Biostar
Pharmaceuticals, Inc.
(Registrant)
|
|
|
|
|
By:
|
/s/
Elaine
Zhao
|
|
Elaine
Zhao
|
|
Chief
Financial Officer
|